Background: The aim of the study was to determine whether or not uraemia has an effect on cyclosporine A intestinal resorption.
Methods And Results: Model experiments were conducted in rats to monitor the effect of acute uraemia (bilateral nephrectomy) on the kinetics of cyclosporine A. Using intragastric tube, Cyclosporine A was administered to one group of rats in the form of Consupren (Galena, Czech Republic) and to another group in the form of Sandimmune (Sandoz, Switzerland), at a dose of 10 mg/kg/24 h either case. Blood levels of cyclosporine A were determined using RIA and specific and non-specific antibodies (cyclosporine and its metabolites). Cyclosporine A kinetics in nephrectomized rats was compared with that in control rats and in rats undergoing sham nephrectomy. The blood levels of cyclosporine A were significantly lower, and the area under the curve (AUC) of blood cyclosporine A in nephrectomized rats significantly smaller than in control rats. No significant differences in the evaluated parameters after Consupren or Sandimmune were observed.
Conclusions: Our findings support the hypothesis that uraemia decreases cyclosporine A availability. The results suggest that the changes in cyclosporine A kinetics in nephrectomized rats following Consupren and Sandimmune administration are of the same character.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
sGC stimulator (BAY 41-8543) combined with PDE9 inhibitor (BAY 73-6691) reduces renal fibrosis in 5/6 nephrectomized rats.
Basic Clin Pharmacol Toxicol
January 2025
Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology/Pneumology), University Medical Centre Mannheim, University of Heidelberg, Germany.
Renal fibrosis is closely related to the prognosis of chronic kidney disease (CKD). The increase in cGMP reduces renal fibrosis. Soluble guanylate cyclase (sGC) and phosphodiesterase (PDE) are key enzymes that maintain cGMP levels.
View Article and Find Full Text PDFComparison of sGC activator and sGC stimulator in 5/6 nephrectomized rats on high-salt-diet.
Front Pharmacol
October 2024
Fifth Department of Medicine (Nephrology/Endocrinology/Rheumatology/Pneumology), University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany.
Article Synopsis
- Soluble guanylate cyclase (sGC) stimulators and activators potentially improve kidney function in chronic kidney disease (CKD) models by boosting levels of cyclic guanosine monophosphate (cGMP), but their effects during oxidative stress hadn't been compared previously.
- A study compared the effects of two compounds, BAY 41-8543 (an sGC stimulator) and BAY 60-2770 (an sGC activator), on CKD progression in rats with significant kidney damage on a high salt diet over 11 weeks.
- While both compounds lowered blood pressure, only BAY 60-2770 effectively reduced kidney fibrosis and improved outcomes related to proteins tied to fibrosis and apoptosis, indicating that sGC
Effect of phosphatase and tensin homolog-induced putative kinase 1/ E3 ubiquitin ligase Parkin mediated mitochondrial autophagy on chronic kidney disease myocardial injury and the intervention mechanism of Shenshuai recipe.
J Tradit Chin Med
October 2024
Department of Anorectal, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang 330000, China.
Article Synopsis
- - The study aimed to evaluate the protective effects of the Shenshuai recipe (SSR) on myocardial injury in chronic kidney disease (CKD) by analyzing the role of the PINK1/Parkin mitochondrial autophagy pathway.
- - Forty-eight nephrectomized rats were divided into groups for different treatments, including control and SSR, and were monitored for changes in cardiac function, biochemical markers, and myocardial tissue characteristics over six weeks.
- - Results showed SSR improved heart function, reduced harmful enzyme levels, and enhanced autophagy markers in the myocardium, indicating its potential as a treatment for CKD-related heart injuries.
Barleriside A, an aryl hydrocarbon receptor antagonist, ameliorates podocyte injury through inhibiting oxidative stress and inflammation.
Front Pharmacol
August 2024
School of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Introduction: Increasing evidence shows that hyperactive aryl hydrocarbon receptor (AHR) signalling is involved in renal disease. However, no currently available intervention strategy is effective in halting disease progression by targeting the AHR signalling. Our previous study showed that barleriside A (BSA), a major component of , exhibits renoprotective effects.
View Article and Find Full Text PDFAntibody to Endogenous Cardiotonic Steroid Reverses Vascular Fibrosis and Restores Vasorelaxation in Chronic Kidney Disease.
Int J Mol Sci
August 2024
Padakonn Pharma, Puskini 9, 20309 Narva, Estonia.
Marinobufagenin (MBG) is implicated in chronic kidney disease, where it removes Fli1-induced inhibition of the collagen-1. We hypothesized that (i) in nephrectomized rats, aortic fibrosis develops due to elevated plasma MBG and inhibited Fli1, and (ii) that the antibody to MBG reduces collagen-1 and improves vasodilatation. A partial nephrectomy was performed in male Sprague-Dawley rats.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!